: iStockAnalyst.com Symbols Feed

Clolar Gets Cool Reception From FDA And Up For Approval (GENZ, VION)

Wed, 02 Sep 2009 16:04:40 GMT

Genzyme Corporation (Nasdaq:GENZ) has a new drug application for their new drug Clofarabine ( Clolar), a leukemia drug that will be used to treat older patients.[More...]

FDA Extreme Trades: 16 Stocks Under $5

Sat, 27 Jun 2009 20:50:19 GMT

Below are FDA extreme trades among 16 companies with stock prices under $5 from the BioMedReports.com FDA Calendar (database includes 225 entries as of 6/27/09) which have pending FDA decisions for either new drug products, biological agents, medical devices, or diagnostic tests that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of (...)[More...]

FDA Calendar Stocks On The Move: DSCO, VION, NFLD

Thu, 16 Apr 2009 20:05:12 GMT

Below is a summary of updates to the BioMedReports.com database of 241 entries included in the FDA and Clinical Trial Calendars. 1.) Vion Pharma (VION.OB): Onrigin (laromustine) Injection (formerly known as Cloretazine or VNP40101M) NDA requesting approval as a single agent for remission induction treatment for patients age 60 and older with de novo poor-risk acute myeloid leukemia (AML). The NDA was filed 2/17/09, accepted by FDA for standard, 10-month review on 4/17/09 with a PDUFA decision (...)[More...]

Feel Good Friday: Nailing A Perfect Short Sale On Vermillion, Inc. (VRML)

Sun, 11 May 2008 05:05:32 GMT

Was I bitter that a stupid mistake cost me between $750 and $1,000 in missed profits the first time VRML squeezed the shorts (as I posted helping other, not knowing I was already short!)? You bet I was! Was I going to let it influence my future trades on[More...]

Another Turnaround Tuesday?

Tue, 08 Jan 2008 14:32:22 GMT

Once again, the premarket futures are trying to stimulate some buying interest at the open. Comments from Fed Plosser, a rebound in commodities (oil & gold) and strength in overseas markets are being cited as positive catalysts. We also have some news of some leadership changes at Starbucks (SBUX) and Bear Stearns (BSC). At 10:AM we have the pending home sales index and 50 minutes later Boston Fed President Eric Rosengren will speak. After testing the November lows yesterday, some probably think that it is time to put some cash to work with tight stops at under...[More...]

Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results

Tue, 11 Aug 2009 11:56:00 GMT

VION PHARMACEUTICALS, INC. today announced financial results for the three-month and six-month periods ending June 30, 2009.[More...]

Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)

Mon, 10 Aug 2009 16:23:00 GMT

VION PHARMACEUTICALS, INC. today announced the date and location of the Oncologic Drugs Advisory Committee Meeting at which its lead oncology therapeutic Onrigin Injection will be presented.[More...]

Vion Pharmaceuticals Presents Data on Onrigin(TM) Elderly AML Trials at the ASCO(R) Annual Meeting

Mon, 01 Jun 2009 11:58:00 GMT

VION PHARMACEUTICALS, INC. today announced that an analysis of clinical data of its lead anticancer agent Onrigin Injection in patients over the age of sixty with acute myeloid leukemia was presented in a poster at the 2009 American Society of Clinical Oncology Annual Meeting in Orlando, Florida.[More...]

Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting

Fri, 29 May 2009 11:56:00 GMT

VION PHARMACEUTICALS, INC. today announced that an analysis of clinical data of its lead anticancer agent Onrigin Injection in acute myeloid leukemia would be presented in a poster at the 2009 American Society of Clinical Oncology Annual Meeting in Orlando, Florida.[More...]

Vion Pharmaceuticals Reports 2009 First Quarter Results

Mon, 11 May 2009 20:48:00 GMT

NEW HAVEN, Conn., May 11 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (BULLETIN BOARD: VION) today announced financial results for the first quarter of 2009.
The Company reported ending the quarter with $30.0 million in cash and cash equivalents.
In February 2009, the Company submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its lead anticancer agent Onrigin (laromustine) Injection for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML).

[More...]